Pharma Open Innovation Symposium

Over three days, the Summit will attract over 175 senior-level decision makers working in drug discovery from the UK, Europe and US’s leading pharmaceutical, biotech, academic and research institutions.  This prestigious event provides a forum for R&D and drug discovery practitioners and prominent innovators to learn more about key solutions being provided to their industry, network with their peers, and address key industry concerns through a series of cutting edge conference presentations in a professional yet relaxed environment.

THE SUMMIT & SYMPOSIUM

In keeping with Oxford Global’s highly successful drug discovery series, an expert panel of speakers will present a full conference programme covering science, technology, strategy, data management and informatics, allowing attendees to gain an essential industry update.  The symposium will be chaired by Thomas Senderovitz, Senior Vice President Global Development, Grunenthal. Key topics include:

OPEN INNOVATION SYMPOSIUM – 8^th June 2010

Defining Open Innovation, Business Models, IP and Collaboration Issues, Academia Open Innovation, Biopharma Open Innovation, Current Open Innovation Initiative and Case Studies

DRUG DISCOVERY SUMMIT – 9^th-10^th June 2010

R&D STRATEGIES & BUSINESS MODELS AND PHARMA/BIOTECH ALLIANCES COLLABORATIONS  –Challenges and strategies to enhance productivity in drug discovery such as open innovation, innovative business models, lean thinking and the benefits of industry and academic alliances

MEDICINAL CHEMISTRY / DRUG DESIGN – Reducing attrition in development, fragment based techniques, flow chemistry, reducing risk of toxicity, structure based discovery as well as hit to lead strategies

SCREENING TECHNIQUES & ASSAY DEVELOPMENT – Improving quality of assays, compound selection, target selection and validation, as well as cost effective lead identification Initiatives for HTS, HCS and label free as well as the potential of pluripotent stem cells

BIOMARKERS & PERSONALISED / TRANSLATIONAL MEDICINE –Translational medicine and diagnostic case studies as well as how Biomarkers facilitate early decision making in early development

BIOINFORMATICS  – In-silico data, predictive modelling, Systems Biology

BIOLOGICS – Strategies to integrate biologics into an organisation, including presentations in phage display in peptides, a panel discussion on biobetters, case study on pepducins

·                      Thomas Senderovitz, Senior Vice President Global Development, Grunenthal

·                      Philip Oliver, Associate Director for Global External R&D Europe, Eli Lilly

·                      Giuseppe Ciaramella, Executive Director, Head of Biotherapeutics, Sandwich, Pfizer

·                      Chas Bountra, Chief Scientist, University of Oxford, Structural Genomics Consortium

·                      Peter Luke, Senior Director, Worldwide Business Development (Strategic Alliances), Pfizer

·                      Patrice Talaga, Director, Chemistry Outsourcing, UCB

·                      Jason Swedlow, Professor of Quantitative Cell Biology Wellcome Trust Centre for Gene Regulation & Expression, College of Life Sciences, University of Dundee

·                      Rob Cooke, Director, Science Environment Development, GSK

Open Innovation prices £400.

Contact us for more details, +44 (0)01865 304 925

Conference Agenda available for download.